(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 38.28% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Harrow's revenue in 2025 is $212,858,000.On average, 3 Wall Street analysts forecast HROW's revenue for 2025 to be $10,482,970,418, with the lowest HROW revenue forecast at $10,307,069,460, and the highest HROW revenue forecast at $10,679,569,923. On average, 3 Wall Street analysts forecast HROW's revenue for 2026 to be $15,371,460,976, with the lowest HROW revenue forecast at $13,946,564,131, and the highest HROW revenue forecast at $17,737,260,960.
In 2027, HROW is forecast to generate $20,771,580,002 in revenue, with the lowest revenue forecast at $18,640,069,964 and the highest revenue forecast at $22,903,090,041.